Literature DB >> 25611236

KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.

Ernest Nadal1, David G Beer, Nithya Ramnath.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25611236      PMCID： PMC4344375          DOI： 10.1097/JTO.0000000000000438

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  2 in total

1.  Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

Authors:  Nathan T Ihle; Lauren A Byers; Edward S Kim; Pierre Saintigny; J Jack Lee; George R Blumenschein; Anne Tsao; Suyu Liu; Jill E Larsen; Jing Wang; Lixia Diao; Kevin R Coombes; Lu Chen; Shuxing Zhang; Mena F Abdelmelek; Ximing Tang; Vassiliki Papadimitrakopoulou; John D Minna; Scott M Lippman; Waun K Hong; Roy S Herbst; Ignacio I Wistuba; John V Heymach; Garth Powis
Journal:  J Natl Cancer Inst       Date:  2012-01-13       Impact factor: 13.506

2.  KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.

Authors:  Ernest Nadal; Guoan Chen; John R Prensner; Hiroe Shiratsuchi; Christine Sam; Lili Zhao; Gregory P Kalemkerian; Dean Brenner; Jules Lin; Rishindra M Reddy; Andrew C Chang; Gabriel Capellà; Felipe Cardenal; David G Beer; Nithya Ramnath
Journal:  J Thorac Oncol       Date:  2014-10       Impact factor: 15.609
  2 in total
  7 in total

1.  MicroRNAs: a new tool in the complex biology of KRAS mutated non-small cell lung cancer?

Authors:  Stéphane Renaud; Joseph Seitlinger; Gilbert Massard
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

2.  Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.

Authors:  Diána Brauswetter; Bianka Gurbi; Attila Varga; Edit Várkondi; Richárd Schwab; Gábor Bánhegyi; Orsolya Fábián; György Kéri; István Vályi-Nagy; István Peták
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

3.  Prognostic value of EGFR and KRAS in resected non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Shi-Ming Zhang; Qing-Ge Zhu; Xiao-Xiao Ding; Song Lin; Jing Zhao; Lei Guan; Ting Li; Bing He; Hu-Qin Zhang
Journal:  Cancer Manag Res       Date:  2018-09-10       Impact factor: 3.989

4.  Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer.

Authors:  Kleita Michaelidou; Chara Koutoulaki; Konstantinos Mavridis; Eleftherios Vorrias; Maria A Papadaki; Anastasios V Koutsopoulos; Dimitrios Mavroudis; Sofia Agelaki
Journal:  Cells       Date:  2020-11-20       Impact factor: 6.600

5.  Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005).

Authors:  Jiyun Lee; Aaron C Tan; Siqin Zhou; Shinkyo Yoon; Siyang Liu; Ken Masuda; Hidetoshi Hayashi; Ullas Batra; Dong-Wan Kim; Yasushi Goto; Sze Huey Tan; Yi-Long Wu; Dae Ho Lee; Daniel S W Tan; Myung-Ju Ahn
Journal:  JTO Clin Res Rep       Date:  2021-12-04

6.  KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.

Authors:  Wei Pan; Yan Yang; Hongcheng Zhu; Youcheng Zhang; Rongping Zhou; Xinchen Sun
Journal:  Oncotarget       Date:  2016-02-16

Review 7.  Molecular genetics and cellular events of K-Ras-driven tumorigenesis.

Authors:  G G Jinesh; V Sambandam; S Vijayaraghavan; K Balaji; S Mukherjee
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.